IndraLab
Statements
reach
"Collectively, our findings suggest that the balanced deubiquitination and ubiquitination of ZEB1 by USP39 and TRIM26 represent a novel mechanism for the progression of HCC, and this discovery provides a promising strategy for targeting USP39 or TRIM26 in the treatment of HCC cases with aberrant ZEB1 expression levels."
"Deubiquitinase <span class="match term0">USP39</span> and E3 ligase TRIM26 balance the level of <span class="match term1">ZEB1</span> ubiquitination and thereby determine the progression of hepatocellular carcinoma"